SEC Form 4 · accession 0001209191-15-087386
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Kay Fenton
Officer — Chief Financial Officer
Period of report
Dec 28, 2015
Accepted (ET)
Dec 30, 2015 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 28, 2015 | M | 43,500 | $1.05 | A | 43,500 | D | |
| Common StockF1 | Dec 28, 2015 | S | 43,500 | $10.08 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF2 | $1.05 | Dec 28, 2015 | M | 43,500 | D | — | Dec 15, 2018 | Common Stock | 43,500 | 0 | D |
Explanation of responses
- F1The price in column 4 is a weighted average price. The actual sale prices for these transactions ranged from $9.97 to $10.21. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F2This option was granted on December 15, 2008 and vested over a four year period with 25% of the shares vesting on the first anniversary of the date of grant and an additional 6.25% vesting at the end of each three month-month period thereafter.
Remarks
The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Fenton on September 24, 2015.